Aurinia Pharmaceuticals (AUPH) News Today $9.03 -0.01 (-0.11%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Short Interest UpdateAurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) was the target of a significant decline in short interest in November. As of November 30th, there was short interest totalling 6,220,000 shares, a decline of 9.6% from the November 15th total of 6,880,000 shares. Based on an average daily trading volume, of 1,260,000 shares, the days-to-cover ratio is presently 4.9 days.December 15, 2024 | marketbeat.comInsiders Are Loving These 6 Stocks Right NowDecember 15, 2024 | 247wallst.comAurinia Pharmaceuticals (NASDAQ:AUPH) Downgraded by StockNews.com to "Buy"December 15, 2024 | americanbankingnews.comAurinia Pharmaceuticals (NASDAQ:AUPH) Rating Lowered to "Buy" at StockNews.comStockNews.com cut shares of Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Friday.December 13, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Acquires 89,940 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Charles Schwab Investment Management Inc. grew its holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 13.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 744,050 shares ofDecember 13, 2024 | marketbeat.comImplied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock OptionsDecember 10, 2024 | msn.comWhile institutions own 40% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), retail investors are its largest shareholders with 52% ownershipDecember 6, 2024 | finance.yahoo.comPDT Partners LLC Has $2.21 Million Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)PDT Partners LLC lifted its holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 76.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 301,553 shares of the biotechnology company's stock after acquiring anDecember 1, 2024 | marketbeat.comAlgert Global LLC Sells 65,791 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Algert Global LLC lowered its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 33.9% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 128,013 shares of the biotechnology company's stock after selling 65,791 shares durNovember 30, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Invests $3.33 Million in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 454,259 shares of the biotechnolNovember 25, 2024 | marketbeat.comPositive Outlook for Aurinia Pharmaceuticals Boosted by Favorable Lupus Nephritis GuidelinesNovember 22, 2024 | markets.businessinsider.comAurinia Pharmaceuticals Celebrates New Lupus Nephritis GuidelinesNovember 19, 2024 | markets.businessinsider.comAurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus NephritisNovember 18, 2024 | financialpost.comAurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus NephritisNovember 18, 2024 | businesswire.comGSA Capital Partners LLP Sells 102,373 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)GSA Capital Partners LLP cut its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 44.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 125,645 shares of the bioteNovember 17, 2024 | marketbeat.comAurinia Highlights Lupus Nephritis Breakthroughs at ACR 2024November 16, 2024 | markets.businessinsider.comAurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024November 15, 2024 | businesswire.comAurinia Pharmaceuticals Engages at London ConferenceNovember 15, 2024 | markets.businessinsider.comAurinia to Participate in Jefferies London Healthcare ConferenceNovember 14, 2024 | businesswire.comInsider Selling: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Director Sells 4,557 Shares of StockNovember 13, 2024 | insidertrades.comPositive Outlook on Aurinia Pharmaceuticals Amid Strong Financial Performance and Strategic Cost ManagementNovember 11, 2024 | markets.businessinsider.comResearch Analysts Offer Predictions for AUPH Q1 EarningsAurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) - Investment analysts at Leerink Partnrs lifted their Q1 2025 earnings per share estimates for shares of Aurinia Pharmaceuticals in a note issued to investors on Thursday, November 7th. Leerink Partnrs analyst J. Schwartz now antiNovember 11, 2024 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded at StockNews.comStockNews.com raised Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday.November 8, 2024 | marketbeat.comAurinia Pharmaceuticals: A Potential Buyout Looms On The HorizonNovember 8, 2024 | seekingalpha.comAurinia Pharmaceuticals Inc (AUPH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...November 8, 2024 | finance.yahoo.comAurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Up 11% - Should You Buy?Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Up 11% - Should You Buy?November 7, 2024 | marketbeat.comAurinia Pharmaceuticals, Inc. (AUPH) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comShareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) are in the red if they invested three years agoNovember 2, 2024 | finance.yahoo.comAurinia Pharmaceuticals (AUPH) Scheduled to Post Earnings on ThursdayAurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports.October 31, 2024 | marketbeat.comAurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024October 30, 2024 | businesswire.comAurinia Pharmaceuticals (NASDAQ:AUPH) Stock, Short Interest ReportOctober 19, 2024 | benzinga.comAurinia Pharmaceuticals (NASDAQ:AUPH) Stock Quotes, Forecast and News SummaryOctober 19, 2024 | benzinga.comAQR Capital Management LLC Takes Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)AQR Capital Management LLC purchased a new position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 202,241 shares of the biotechnologOctober 12, 2024 | marketbeat.comSG Americas Securities LLC Grows Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)SG Americas Securities LLC grew its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 4,307.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 547,727October 7, 2024 | marketbeat.comAlgert Global LLC Acquires 100,104 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Algert Global LLC lifted its holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 106.8% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 193,804 shares of the biotechnology compaOctober 5, 2024 | marketbeat.comStonepine Capital Management LLC Takes $1.71 Million Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Stonepine Capital Management LLC bought a new position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 300,000 shares of the biotechOctober 1, 2024 | marketbeat.comShort Interest in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Declines By 13.0%Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) was the target of a significant drop in short interest in September. As of September 15th, there was short interest totalling 7,580,000 shares, a drop of 13.0% from the August 31st total of 8,710,000 shares. Based on an average daily trading volume, of 1,420,000 shares, the days-to-cover ratio is presently 5.3 days.September 28, 2024 | marketbeat.comAurinia Pharmaceuticals: Strategic Growth and Buy Rating Amidst Japan Market Expansion and M&A PotentialSeptember 27, 2024 | markets.businessinsider.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Could Be Less Than A Year Away From ProfitabilitySeptember 27, 2024 | finance.yahoo.comAurinia Announces Japan Approval of LUPKYNIS ® (Voclosporin) to Treat Lupus NephritisSeptember 26, 2024 | businesswire.comArmistice Capital LLC Lowers Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Armistice Capital LLC reduced its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 9.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,136,000 shares of the bSeptember 26, 2024 | marketbeat.comAurinia Pharma Gets Approval in Japan for Lupus TreatmentSeptember 24, 2024 | marketwatch.comAurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus NephritisSeptember 24, 2024 | stockhouse.comAurinia Announces Approval Of LUPKYNIS In Japan - Quick FactsSeptember 24, 2024 | markets.businessinsider.comAurinia Pharmaceuticals: This Recovery Can ContinueSeptember 18, 2024 | seekingalpha.comAurinia Pharmaceuticals (NASDAQ:AUPH) Trading 4% Higher Aurinia Pharmaceuticals (NASDAQ:AUPH) Trading Up 4%September 16, 2024 | marketbeat.comAurinia Pharmaceuticals' (AUPH) "Overweight" Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating and set a $10.00 price target on shares of Aurinia Pharmaceuticals in a research report on Monday.September 16, 2024 | marketbeat.comBank of New York Mellon Corp Raises Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Bank of New York Mellon Corp raised its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 18.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 488,721 shares ofSeptember 16, 2024 | marketbeat.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock Holdings Reduced by Jupiter Asset Management Ltd.Jupiter Asset Management Ltd. cut its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 35.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 158,497 sharesSeptember 14, 2024 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) Shares Gap Up to $6.58Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Gap Up to $6.58September 13, 2024 | marketbeat.com Get Aurinia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news. Register For The Webinar To Discover AUPH Media Mentions By Week AUPH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AUPH News Sentiment▼0.970.61▲Average Medical News Sentiment AUPH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AUPH Articles This Week▼33▲AUPH Articles Average Week Get Aurinia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TGTX News VKTX News BBIO News GRFS News CRNX News ALKS News AXSM News RARE News BHVN News APLS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AUPH) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurinia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
